FDA Updates Drug Registration Rules for Multi-Site Makers
Published Date: 7/13/2026
Proposed Rule
Summary
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
Analyzed Economic Effects
7 provisions identified: 3 benefits, 4 costs, 0 mixed.
Single registration for distributed makers
If you run a drug manufacturing business that uses a hub-and-spoke distributed manufacturing model, the FDA is proposing a new pathway that would let the whole distributed manufacturing establishment (the hub plus its DM units) register as a single establishment instead of each site registering separately. The proposal also treats adding or removing a DM unit or relocating a mobile DM unit as an expedited update to that single registration.
New quality and inspection requirements
To qualify to register as a single distributed manufacturing establishment, the FDA proposes that the hub and its DM units must operate under one management with a unified pharmaceutical quality system (UPQS) and that the DME must have been subject to a preapproval inspection for at least one drug in each profile class manufactured by the DME. These requirements are part of the proposed definition of a DME.
Streamlined pathway excludes unaffiliated CMOs
The proposed rule would not allow multiple unaffiliated contract manufacturing organizations (CMOs) or third-party relabelers/repackers/salvagers that are not under the manufacturer's ownership or control to use the single-registration DME pathway. Those unaffiliated third parties would need to register and list separately under current rules.
Foreign establishments must register and list
The FDA proposes to amend registration and listing rules to clarify that each foreign establishment that manufactures, repacks, relabels, or salvages a drug that is imported or offered for import into the United States must register and provide drug listing information, regardless of whether the drug is further processed at a different foreign establishment before import. This change aligns the regulations with section 2511 of the PREVENT Pandemics Act.
Greater supply chain visibility and shortages help
The FDA says unquantified benefits of the proposal include greater visibility into the drug supply chain, which the Agency expects will help prevent and mitigate drug shortages and aid in preventing importation of adulterated or misbranded drugs.
Include similar OTC products under one DME
A DME registered under the proposed rule may manufacture non-application products (for example, over-the-counter monograph drugs) as long as each such non-application product is of the same FDA profile class as one or more drugs the DME manufactures under an approved application that describes use of a decentralized manufacturing strategy.
Estimated annualized compliance costs (FDA/industry)
FDA estimates annualized net costs of this proposal to be approximately $532,811 to $664,495 at a 7% discount rate (primary estimate $583,958), and $482,472 to $606,839 at a 3% discount rate (primary estimate $533,771). These estimates include costs to drug manufacturers for reading and understanding the rule and costs to FDA for updating submission schemas and tools.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Previous / Next Documents
Previous: 2026-14048 — Fisheries of the Caribbean, Gulf of America, and South Atlantic; Snapper-Grouper Fishery of the South Atlantic Region; Abbreviated Framework Amendment 5
The government wants to update fishing rules for blueline tilefish in the South Atlantic to keep the fish population healthy and fishing fair. These changes affect fishermen and businesses by adjusting how much fish can be caught, based on the latest science. Comments on the plan are open until August 12, 2026, so now’s the time to speak up!
Next: 2026-14074 — New Agency Information Collection Activity Under OMB Review: Insider Threat Incident Reporting Tool
The TSA is rolling out a new tool for the public to report insider threats—people who might cause security problems from the inside. They’re asking for your feedback by August 12, 2026, to make sure this tool works well and isn’t too much hassle. This new process aims to keep everyone safer without costing extra money or time.